Table 1

Overview of reviewed preclinical studies on LB100. Studies reflect a review of the literature as of May 1, 2022.

Investigators (year)Tumor typeTreatment methodOutcome
Cui et al.21 (2020)GlioblastomaLB100 and CAR-T cell therapyAnti-CAIX CAR-T cell therapy and LB100 combination therapy significantly increased tumor-infiltrating lymphocytes (P < 0.05) and prolonged survival (P < 0.001) in xenograft U251-Luc GBM mice.
Maggio et al.22 (2020)GlioblastomaLB100 and PD-1 inhibitionCombination therapy, compared with monotherapy, significantly increased survival of syngeneic GL261-Luc GBM mice (P < 0.05). Complete tumor regression occurred in 25% of combination-treated mice but was not observed in other treatment or control groups.
Mirzapoiazova et al.23 (2022)Small-cell lung cancerLB100, carboplatin, atezolizumab, and PD-L1 inhibitionLB100 and carboplatin combination treatment resulted in significantly smaller tumor size in xenograft SCLC mice than controls (P < 0.001). LB100 administration also increased carboplatin uptake in tumor cells (P < 0.001). Triple therapy with LB100, the PD-1 inhibitor atezolizumab, and anti-PD-L1 starkly destroyed H446 SCLC tumor cell spheroids, increased infiltration by activated T cells, and increased tumor cell death in vitro.
Uddin et al.24 (2020)Triple-negative breast cancerLB100 onlyLB100 monotherapy significantly decreased tumor volume in mice bearing MB468 TNBC xenografts.
Yen et al.25 (2021)Colorectal cancer, adenocarcinoma, triple-negative breast cancer, and pancreatic cancerLB100 and PD-1 inhibitionLB100 and anti-PD-1 co-treatment in multiple cancerous syngeneic mouse models resulted in MLH1 protein loss, greater microsatellite instability, and significantly smaller tumor volumes than those in control groups (P = 0.01), corresponding to increased tumor neoantigen expression.
Zhang et al.26 (2015)OsteosarcomaLB100 and cisplatinCombination therapy, compared with cisplatin or LB100 alone, resulted in significantly smaller tumor volumes in mice bearing 143B OS xenografts (P < 0.05). Pulmonary metastases were observed in only 20% of combination-treated mice, compared with 80% of mice treated with cisplatin alone mice and 100% of mice treated with LB100 alone.
Liu et al.27 (2018)Mucoepidermoid carcinomaLB100 and cisplatinCo-treatment of MEC cells with LB100 and cisplatin decreased PP2A activity to 84.98% of control levels in vitro. Combination-treated xenograft UM-HMC1 MEC mice also exhibited a significantly smaller tumor volume than did mice treated with either drug alone.
Song et al.28 (2021)Esophageal squamous cell carcinomaLB100 and paclitaxelLB100 administration attenuated PP2A expression and decreased MCL1 protein levels (P < 0.001) in paclitaxel-resistant ESCC in vitro. In vivo, mouse models of DR150 paclitaxel-resistant ESCC were treated with LB100 monotherapy and showed significant inhibition of tumor growth (P < 0.05).
Hu et al.29 (2017)Acute myelogenous leukemiaLB100 and daunorubicinLB100 monotherapy increased the proportion of patient-derived AML cells in G2/M phase from 13.4% to 31.5% in vitro. LB100 and daunorubicin combination therapy significantly increased cytolysis in these cell lines in vitro (P < 0.01).
Lai et al.30 (2018)Chronic myelogenous leukemiaLB100 and dasatinibCombination therapy resulted in significantly fewer BCR-ABL transcripts in transgenic CML mice than controls (P < 0.01). The combination also yielded a survival benefit over dasatinib monotherapy (P = 0.018) and vehicle (P = 0.001).
Ho et al.31 (2018)MeningiomaLB100 and radiationLB100 and concomitant radiation induced cell death by mitotic catastrophe in vitro. Mice bearing malignant IOMM-LEE meningioma xenografts demonstrated a survival benefit when treated with combination therapy compared with either monotherapy (P < 0.05).
Hao et al.32 (2018)ChordomaLB100 and radiationCo-treatment increased the proportion of cells arrested in G2/M phase of the cell cycle in vitro. Tumor size was significantly smaller in xenograft U-CH1 chordoma mice treated with combination therapy than in mice in the control (P = 0.028), LB100 alone (P = 0.0014), or radiation alone (P = 0.0273) groups.